| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bacteremia | 10 | 2019 | 1372 | 1.85 | Why? |
| Anti-Bacterial Agents | 22 | 2021 | 10083 | 1.62 | Why? |
| beta-Lactams | 5 | 2019 | 210 | 1.61 | Why? |
| Rosuvastatin Calcium | 3 | 2018 | 89 | 1.55 | Why? |
| Teicoplanin | 2 | 2021 | 191 | 1.53 | Why? |
| HIV Infections | 17 | 2021 | 11620 | 1.44 | Why? |
| Anti-HIV Agents | 8 | 2020 | 2209 | 1.37 | Why? |
| Gram-Positive Bacterial Infections | 2 | 2021 | 323 | 1.33 | Why? |
| Enterobacteriaceae Infections | 6 | 2019 | 529 | 1.31 | Why? |
| Raltegravir Potassium | 2 | 2017 | 132 | 1.27 | Why? |
| Anticholesteremic Agents | 2 | 2018 | 186 | 1.18 | Why? |
| Hyperlipidemias | 2 | 2018 | 290 | 1.16 | Why? |
| Escherichia coli Infections | 2 | 2018 | 348 | 1.11 | Why? |
| beta-Lactam Resistance | 3 | 2019 | 150 | 0.94 | Why? |
| Thienamycins | 3 | 2018 | 72 | 0.91 | Why? |
| beta-Lactamase Inhibitors | 3 | 2019 | 104 | 0.91 | Why? |
| Minocycline | 4 | 2018 | 101 | 0.90 | Why? |
| Intraabdominal Infections | 3 | 2018 | 90 | 0.86 | Why? |
| Klebsiella Infections | 5 | 2017 | 466 | 0.85 | Why? |
| Klebsiella pneumoniae | 6 | 2019 | 658 | 0.84 | Why? |
| Antifungal Agents | 4 | 2018 | 1828 | 0.83 | Why? |
| Off-Label Use | 3 | 2021 | 553 | 0.82 | Why? |
| HIV-1 | 7 | 2020 | 3365 | 0.82 | Why? |
| Tuberculosis, Spinal | 1 | 2019 | 9 | 0.80 | Why? |
| Drug Resistance, Multiple, Bacterial | 7 | 2019 | 1115 | 0.71 | Why? |
| Nevirapine | 1 | 2017 | 57 | 0.69 | Why? |
| Ritonavir | 5 | 2020 | 4212 | 0.66 | Why? |
| Blood Culture | 1 | 2019 | 308 | 0.66 | Why? |
| Echinocandins | 1 | 2018 | 139 | 0.65 | Why? |
| Candidemia | 2 | 2018 | 353 | 0.65 | Why? |
| Sepsis | 8 | 2021 | 3517 | 0.64 | Why? |
| Wound Infection | 1 | 2017 | 66 | 0.64 | Why? |
| Darunavir | 2 | 2017 | 477 | 0.64 | Why? |
| Maintenance Chemotherapy | 1 | 2017 | 133 | 0.64 | Why? |
| Pyridazines | 1 | 2017 | 86 | 0.63 | Why? |
| Microbiological Techniques | 1 | 2018 | 232 | 0.62 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.61 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2017 | 952 | 0.60 | Why? |
| Blood Specimen Collection | 1 | 2019 | 387 | 0.59 | Why? |
| Organ Transplantation | 3 | 2020 | 2616 | 0.56 | Why? |
| Liver Cirrhosis | 4 | 2019 | 1810 | 0.56 | Why? |
| Ceftazidime | 4 | 2019 | 134 | 0.55 | Why? |
| Quality Assurance, Health Care | 1 | 2019 | 596 | 0.55 | Why? |
| Vitamin D Deficiency | 2 | 2019 | 1782 | 0.55 | Why? |
| Patient Participation | 1 | 2021 | 829 | 0.54 | Why? |
| Prosthesis-Related Infections | 2 | 2017 | 302 | 0.53 | Why? |
| Clostridium Infections | 2 | 2019 | 595 | 0.53 | Why? |
| Invasive Fungal Infections | 1 | 2018 | 274 | 0.52 | Why? |
| Escherichia coli | 2 | 2018 | 1547 | 0.51 | Why? |
| Liver Failure, Acute | 1 | 2017 | 279 | 0.51 | Why? |
| Azabicyclo Compounds | 3 | 2019 | 91 | 0.50 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.50 | Why? |
| Enoxaparin | 1 | 2020 | 1064 | 0.50 | Why? |
| Coinfection | 4 | 2021 | 6820 | 0.49 | Why? |
| Spinal Cord Injuries | 1 | 2017 | 270 | 0.48 | Why? |
| Metabolic Diseases | 1 | 2017 | 505 | 0.44 | Why? |
| Renal Insufficiency, Chronic | 2 | 2018 | 2654 | 0.44 | Why? |
| Tuberculosis | 2 | 2017 | 2895 | 0.43 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.43 | Why? |
| Pressure Ulcer | 1 | 2017 | 398 | 0.43 | Why? |
| Cystic Fibrosis | 1 | 2020 | 1104 | 0.42 | Why? |
| Enterobacteriaceae | 4 | 2018 | 395 | 0.42 | Why? |
| CD4 Lymphocyte Count | 5 | 2020 | 1517 | 0.42 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.41 | Why? |
| Bacterial Infections | 3 | 2018 | 2229 | 0.40 | Why? |
| Urban Health | 1 | 2013 | 382 | 0.40 | Why? |
| Drug Therapy, Combination | 5 | 2020 | 7268 | 0.39 | Why? |
| Viral Load | 7 | 2020 | 15850 | 0.38 | Why? |
| Multimodal Imaging | 1 | 2014 | 534 | 0.38 | Why? |
| Endocarditis, Bacterial | 1 | 2014 | 344 | 0.37 | Why? |
| Liver Transplantation | 4 | 2018 | 2864 | 0.37 | Why? |
| Transplant Recipients | 3 | 2020 | 4982 | 0.36 | Why? |
| Positron-Emission Tomography | 1 | 2014 | 802 | 0.36 | Why? |
| Skin Diseases, Bacterial | 2 | 2021 | 105 | 0.36 | Why? |
| Heart Valve Prosthesis | 1 | 2014 | 533 | 0.35 | Why? |
| Thrombophilia | 1 | 2020 | 1935 | 0.34 | Why? |
| Refugees | 1 | 2017 | 809 | 0.34 | Why? |
| Shock, Septic | 1 | 2017 | 1313 | 0.34 | Why? |
| Ambulatory Care | 2 | 2021 | 4947 | 0.33 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.33 | Why? |
| Middle Aged | 50 | 2021 | 270681 | 0.33 | Why? |
| Italy | 25 | 2021 | 38444 | 0.32 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.32 | Why? |
| Carbapenems | 3 | 2019 | 343 | 0.32 | Why? |
| Male | 58 | 2021 | 367725 | 0.32 | Why? |
| Plasma | 1 | 2017 | 1809 | 0.32 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.30 | Why? |
| Hydroxychloroquine | 6 | 2020 | 12447 | 0.30 | Why? |
| beta-Lactamases | 5 | 2019 | 759 | 0.30 | Why? |
| Humans | 90 | 2021 | 930598 | 0.29 | Why? |
| Adult | 36 | 2021 | 244371 | 0.29 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.29 | Why? |
| Female | 54 | 2021 | 380317 | 0.29 | Why? |
| Prospective Studies | 13 | 2021 | 43301 | 0.28 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.28 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.28 | Why? |
| Aged | 38 | 2021 | 215776 | 0.27 | Why? |
| Risk Factors | 18 | 2020 | 71621 | 0.27 | Why? |
| Invasive Pulmonary Aspergillosis | 2 | 2021 | 634 | 0.27 | Why? |
| Microbial Sensitivity Tests | 5 | 2019 | 2886 | 0.26 | Why? |
| Disease Management | 5 | 2019 | 6841 | 0.25 | Why? |
| Retrospective Studies | 24 | 2021 | 105322 | 0.25 | Why? |
| Postoperative Complications | 4 | 2019 | 5861 | 0.25 | Why? |
| Cross Infection | 5 | 2021 | 8675 | 0.24 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.24 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.23 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.23 | Why? |
| Candidiasis | 2 | 2017 | 334 | 0.22 | Why? |
| Radiography, Thoracic | 1 | 2017 | 5486 | 0.21 | Why? |
| Endocarditis | 2 | 2017 | 368 | 0.21 | Why? |
| Treatment Outcome | 13 | 2021 | 51732 | 0.20 | Why? |
| Pseudomonas Infections | 3 | 2018 | 425 | 0.20 | Why? |
| CD4-CD8 Ratio | 1 | 2020 | 235 | 0.20 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.20 | Why? |
| Boronic Acids | 1 | 2019 | 30 | 0.20 | Why? |
| Glomerular Filtration Rate | 2 | 2018 | 1262 | 0.20 | Why? |
| Recurrence | 3 | 2019 | 3675 | 0.20 | Why? |
| Survival Analysis | 5 | 2020 | 7592 | 0.19 | Why? |
| Respiratory Insufficiency | 4 | 2021 | 7301 | 0.19 | Why? |
| Tick Bites | 1 | 2018 | 34 | 0.19 | Why? |
| Valsartan | 1 | 2020 | 206 | 0.19 | Why? |
| Emergency Service, Hospital | 3 | 2020 | 14232 | 0.19 | Why? |
| Cephalosporins | 2 | 2018 | 250 | 0.19 | Why? |
| Bacteria | 2 | 2021 | 1897 | 0.19 | Why? |
| Infusions, Intravenous | 3 | 2019 | 1224 | 0.18 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.18 | Why? |
| Environment Design | 1 | 2020 | 183 | 0.18 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2018 | 214 | 0.18 | Why? |
| Hypertrophy, Left Ventricular | 1 | 2021 | 219 | 0.18 | Why? |
| Pneumonia, Viral | 13 | 2020 | 243684 | 0.18 | Why? |
| Injections, Intravenous | 1 | 2019 | 381 | 0.18 | Why? |
| Proteus mirabilis | 1 | 2017 | 11 | 0.18 | Why? |
| Combined Modality Therapy | 2 | 2020 | 3395 | 0.18 | Why? |
| Proteus Infections | 1 | 2017 | 9 | 0.18 | Why? |
| Colistin | 2 | 2017 | 217 | 0.18 | Why? |
| Staphylococcal Infections | 2 | 2018 | 1099 | 0.17 | Why? |
| Drug Combinations | 4 | 2020 | 3852 | 0.17 | Why? |
| Ethambutol | 1 | 2017 | 34 | 0.17 | Why? |
| Incidence | 6 | 2020 | 25622 | 0.17 | Why? |
| Lymphoma, Follicular | 1 | 2018 | 109 | 0.17 | Why? |
| Quinazolinones | 1 | 2018 | 135 | 0.17 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.17 | Why? |
| Arrhythmias, Cardiac | 2 | 2021 | 2510 | 0.16 | Why? |
| Proviruses | 1 | 2017 | 82 | 0.16 | Why? |
| Anti-Inflammatory Agents | 3 | 2020 | 6153 | 0.16 | Why? |
| Oxygen Inhalation Therapy | 2 | 2020 | 3629 | 0.16 | Why? |
| Isoniazid | 1 | 2017 | 105 | 0.16 | Why? |
| Aged, 80 and over | 13 | 2021 | 88759 | 0.16 | Why? |
| Electrocardiography | 2 | 2021 | 3957 | 0.16 | Why? |
| Pulmonary Aspergillosis | 1 | 2021 | 408 | 0.16 | Why? |
| Lamivudine | 1 | 2017 | 210 | 0.16 | Why? |
| Graft Rejection | 3 | 2018 | 1766 | 0.16 | Why? |
| Debridement | 1 | 2017 | 172 | 0.15 | Why? |
| Parasitic Diseases | 1 | 2017 | 84 | 0.15 | Why? |
| Tomography, X-Ray Computed | 4 | 2020 | 25144 | 0.15 | Why? |
| Intestinal Perforation | 1 | 2018 | 178 | 0.15 | Why? |
| Acinetobacter Infections | 1 | 2019 | 273 | 0.15 | Why? |
| Kidney Function Tests | 1 | 2018 | 520 | 0.15 | Why? |
| Endoscopy, Digestive System | 1 | 2020 | 352 | 0.15 | Why? |
| Intestinal Obstruction | 1 | 2018 | 197 | 0.15 | Why? |
| Glycopeptides | 1 | 2018 | 199 | 0.15 | Why? |
| Acinetobacter baumannii | 1 | 2019 | 378 | 0.15 | Why? |
| Soft Tissue Infections | 1 | 2017 | 116 | 0.15 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.15 | Why? |
| Atazanavir Sulfate | 1 | 2017 | 213 | 0.15 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.15 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.15 | Why? |
| Multivariate Analysis | 4 | 2020 | 5440 | 0.15 | Why? |
| Anti-Infective Agents | 2 | 2017 | 1766 | 0.15 | Why? |
| Dysbiosis | 1 | 2021 | 685 | 0.14 | Why? |
| Travel Medicine | 1 | 2018 | 335 | 0.14 | Why? |
| Reoperation | 2 | 2017 | 544 | 0.14 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.14 | Why? |
| Fatty Acids, Omega-3 | 1 | 2018 | 306 | 0.14 | Why? |
| Biofilms | 1 | 2017 | 304 | 0.14 | Why? |
| Gram-Negative Bacteria | 1 | 2019 | 473 | 0.14 | Why? |
| Fluorine Radioisotopes | 1 | 2014 | 59 | 0.14 | Why? |
| Plasmids | 1 | 2017 | 840 | 0.13 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.13 | Why? |
| Drug Administration Schedule | 1 | 2021 | 2324 | 0.13 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.13 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.13 | Why? |
| Decision Support Techniques | 1 | 2021 | 903 | 0.13 | Why? |
| Young Adult | 11 | 2020 | 93724 | 0.13 | Why? |
| HIV Protease Inhibitors | 1 | 2017 | 434 | 0.13 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.13 | Why? |
| Cholesterol, LDL | 1 | 2017 | 499 | 0.13 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.13 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.13 | Why? |
| Heart Valve Diseases | 1 | 2017 | 355 | 0.12 | Why? |
| Candida | 1 | 2017 | 425 | 0.12 | Why? |
| Hospital Units | 1 | 2020 | 1017 | 0.12 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2017 | 669 | 0.12 | Why? |
| Adolescent | 9 | 2020 | 86841 | 0.12 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Purines | 1 | 2018 | 816 | 0.12 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.12 | Why? |
| Antimicrobial Stewardship | 2 | 2019 | 931 | 0.12 | Why? |
| Neglected Diseases | 1 | 2017 | 381 | 0.12 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2021 | 2309 | 0.12 | Why? |
| Nitriles | 1 | 2017 | 1053 | 0.11 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.11 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.11 | Why? |
| Heart Valve Prosthesis Implantation | 2 | 2017 | 552 | 0.11 | Why? |
| Vascular Surgical Procedures | 1 | 2020 | 882 | 0.11 | Why? |
| Vascular Diseases | 1 | 2020 | 846 | 0.11 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.11 | Why? |
| Pandemics | 13 | 2021 | 389249 | 0.11 | Why? |
| DNA, Viral | 2 | 2018 | 2521 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Organ Dysfunction Scores | 1 | 2017 | 1475 | 0.11 | Why? |
| Tandem Mass Spectrometry | 1 | 2017 | 1031 | 0.11 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.11 | Why? |
| Logistic Models | 3 | 2020 | 9089 | 0.11 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.10 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.10 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 877 | 0.10 | Why? |
| Homosexuality, Male | 1 | 2019 | 1158 | 0.10 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.10 | Why? |
| Preoperative Care | 1 | 2020 | 1515 | 0.10 | Why? |
| Endothelial Cells | 1 | 2020 | 2048 | 0.10 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.10 | Why? |
| Heart Transplantation | 1 | 2020 | 1293 | 0.10 | Why? |
| Prevalence | 3 | 2017 | 25773 | 0.10 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.10 | Why? |
| Sexual and Gender Minorities | 1 | 2019 | 1019 | 0.10 | Why? |
| Hyperglycemia | 1 | 2020 | 1363 | 0.09 | Why? |
| Graft Survival | 1 | 2012 | 587 | 0.09 | Why? |
| Comorbidity | 9 | 2021 | 34796 | 0.09 | Why? |
| Algorithms | 3 | 2021 | 7346 | 0.09 | Why? |
| Gastroenterology | 1 | 2020 | 1352 | 0.09 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.09 | Why? |
| Radiopharmaceuticals | 1 | 2014 | 763 | 0.09 | Why? |
| Guidelines as Topic | 2 | 2019 | 2844 | 0.09 | Why? |
| Hepacivirus | 1 | 2018 | 1509 | 0.09 | Why? |
| Prognosis | 6 | 2020 | 32490 | 0.09 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.09 | Why? |
| Interferons | 1 | 2020 | 2885 | 0.09 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.09 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.09 | Why? |
| Gastrointestinal Microbiome | 1 | 2021 | 1961 | 0.09 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.09 | Why? |
| Critical Illness | 6 | 2021 | 17281 | 0.09 | Why? |
| Antiviral Agents | 5 | 2020 | 41703 | 0.09 | Why? |
| Lung | 3 | 2021 | 31049 | 0.09 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.09 | Why? |
| Gentamicins | 2 | 2017 | 76 | 0.08 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.08 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.08 | Why? |
| Lymphocyte Count | 1 | 2019 | 4758 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.08 | Why? |
| Aortic Valve | 1 | 2014 | 664 | 0.08 | Why? |
| False Negative Reactions | 1 | 2014 | 1785 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2014 | 1153 | 0.08 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.08 | Why? |
| Age Factors | 3 | 2017 | 21039 | 0.08 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Colorectal Neoplasms | 1 | 2018 | 1884 | 0.07 | Why? |
| Patient Outcome Assessment | 2 | 2019 | 707 | 0.07 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.07 | Why? |
| Hospitals | 3 | 2020 | 11793 | 0.06 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.06 | Why? |
| Intensive Care Units | 5 | 2021 | 29594 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.06 | Why? |
| Hepatitis C, Chronic | 1 | 2012 | 973 | 0.06 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.06 | Why? |
| Elective Surgical Procedures | 1 | 2020 | 5338 | 0.06 | Why? |
| Neutropenia | 1 | 2005 | 388 | 0.06 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.05 | Why? |
| Cross-Sectional Studies | 4 | 2017 | 53120 | 0.05 | Why? |
| Piperacillin | 1 | 2019 | 63 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.05 | Why? |
| Aldehyde Oxidase | 1 | 2018 | 10 | 0.05 | Why? |
| Colostomy | 1 | 2018 | 33 | 0.05 | Why? |
| Kaplan-Meier Estimate | 2 | 2019 | 4260 | 0.05 | Why? |
| Kidney | 1 | 2013 | 3648 | 0.05 | Why? |
| Heart Failure | 1 | 2020 | 6638 | 0.05 | Why? |
| Propensity Score | 2 | 2017 | 2690 | 0.05 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2018 | 88 | 0.05 | Why? |
| Rickettsia Infections | 1 | 2018 | 58 | 0.05 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2005 | 676 | 0.05 | Why? |
| Enterocolitis, Pseudomembranous | 1 | 2019 | 93 | 0.05 | Why? |
| Mental Status Schedule | 1 | 2017 | 34 | 0.05 | Why? |
| Self Expandable Metallic Stents | 1 | 2018 | 52 | 0.05 | Why? |
| Bacterial Proteins | 2 | 2017 | 1318 | 0.04 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.04 | Why? |
| Aspergillus | 1 | 2021 | 347 | 0.04 | Why? |
| Rickettsia | 1 | 2018 | 101 | 0.04 | Why? |
| Pseudomonas aeruginosa | 2 | 2018 | 652 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2021 | 793 | 0.04 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.04 | Why? |
| Interferon beta-1a | 1 | 2020 | 316 | 0.04 | Why? |
| Imipenem | 1 | 2017 | 57 | 0.04 | Why? |
| Klebsiella | 1 | 2017 | 35 | 0.04 | Why? |
| Heart Valves | 1 | 2017 | 52 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.04 | Why? |
| Croatia | 1 | 2018 | 360 | 0.04 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 6653 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Causality | 1 | 2021 | 857 | 0.04 | Why? |
| Longevity | 1 | 2018 | 159 | 0.04 | Why? |
| Animals | 3 | 2021 | 78931 | 0.04 | Why? |
| Preoperative Period | 1 | 2017 | 271 | 0.04 | Why? |
| Drug Synergism | 1 | 2019 | 833 | 0.04 | Why? |
| Sex Factors | 1 | 2013 | 11014 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| Colitis | 1 | 2018 | 266 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.04 | Why? |
| South America | 1 | 2017 | 565 | 0.04 | Why? |
| Colectomy | 1 | 2018 | 327 | 0.04 | Why? |
| Candida albicans | 1 | 2016 | 217 | 0.04 | Why? |
| Gene Frequency | 1 | 2020 | 1210 | 0.04 | Why? |
| Patient Reported Outcome Measures | 1 | 2020 | 912 | 0.03 | Why? |
| Fecal Microbiota Transplantation | 1 | 2019 | 372 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Acute-On-Chronic Liver Failure | 1 | 2017 | 237 | 0.03 | Why? |
| Databases, Genetic | 1 | 2020 | 1127 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.03 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2021 | 861 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.03 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2017 | 1335 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Data Accuracy | 1 | 2017 | 715 | 0.03 | Why? |
| Program Evaluation | 1 | 2020 | 1929 | 0.03 | Why? |
| Physical Examination | 1 | 2017 | 755 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.03 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.03 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.03 | Why? |
| Microbiota | 1 | 2021 | 1240 | 0.03 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.03 | Why? |
| Tertiary Care Centers | 2 | 2019 | 8248 | 0.03 | Why? |
| Internal Medicine | 1 | 2016 | 557 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.03 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.02 | Why? |
| Asia | 1 | 2017 | 2399 | 0.02 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Fever | 1 | 2005 | 7795 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1573 | 0.02 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.02 | Why? |
| Delayed Diagnosis | 1 | 2017 | 1529 | 0.02 | Why? |
| Binding Sites | 1 | 2020 | 6201 | 0.02 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.02 | Why? |
| Diarrhea | 1 | 2018 | 2743 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Genetic Variation | 1 | 2020 | 3919 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Global Health | 2 | 2017 | 13911 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Patient Discharge | 1 | 2018 | 5696 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |